Eli Lilly Raises FY23 Revenue Guidance To $33.4B-$33.9B From Prior Guidance Of $31.2B-$31.7B Vs. Consensus Of $31.44B; Sees Adjusted EPS Of $9.70-$9.90 From Prior Guidance Of $8.65-$8.85 Vs. Consensus Of $8.71
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly has increased its FY23 revenue guidance to $33.4B-$33.9B, up from the previous guidance of $31.2B-$31.7B, surpassing the consensus of $31.44B. The company also raised its adjusted EPS forecast to $9.70-$9.90 from the earlier guidance of $8.65-$8.85, beating the consensus of $8.71.
August 08, 2023 | 10:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's raised FY23 revenue and EPS guidance, which surpasses the consensus, indicates strong future performance. This could positively impact the company's stock price in the short term.
Eli Lilly's raised guidance for FY23 revenue and EPS, which is above the consensus, indicates that the company is expecting strong performance in the future. This positive outlook could lead to increased investor confidence and demand for the stock, potentially driving up its price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100